Agios Pharma (AGIO): 'Aqvesme's opportunity in thalassemia reason enough to own the stock,' says analyst
Tweet Send to a Friend
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating and {REMOVEPT} price target on Agios Pharma (NASDAQ: AGIO).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
